NCT01869309 - Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2016

Conditions

Coronary Artery Disease

Interventions

DRUG

Prasugrel

Patients will discontinue ticagrelor treatment and start 10 mg prasugrel daily while continuing 81 mg of aspirin daily.

DRUG

Ticagrelor

Patients will be given 180 mg of Ticagrelor followed by 90 mg twice a day while continuing 81 mg of aspirin daily).

Trial Locations (1)

RECRUITING

Sinai Center for Thrombosis Research, Baltimore